Low-Dose Naltrexone (LDN) for Long COVID: What We Know, What We Don’t, and Who It May Help
Low-dose naltrexone (LDN) has become one of the most discussed “off-label” options for Long COVID — particularly for people whose main symptoms include
fatigue, pain, brain fog, and sleep disturbance. Interest is growing because LDN is often considered
low cost, generally well tolerated, and has plausible effects on immune and neuro-inflammatory pathways.
LDN is not licensed specifically for Long COVID. When used for Long COVID it is prescribed off-label, meaning clinicians may use it based on emerging evidence and clinical judgement where appropriate.
💊 What is low-dose naltrexone?
Naltrexone is a medicine used at much higher doses (commonly 50 mg) for alcohol use disorder and opioid dependence.
“Low-dose naltrexone” typically refers to doses around 1–4.5 mg/day, often prepared by a compounding pharmacy.
At low doses, the intention is not long-term opioid blockade, but rather possible immune modulation and neuro-inflammatory effects.
LDN has also been used off-label in conditions such as fibromyalgia and multiple sclerosis, which share features with Long COVID including fatigue, pain, and nervous-system sensitisation.
🧠 Why might LDN help in Long COVID?
Long COVID is still being defined biologically, but many patients appear to have ongoing issues related to:
- persistent inflammation
- immune dysregulation
- neuro-inflammation (brain/central nervous system inflammation)
- nervous-system sensitisation
Some specialist clinicians note that Long COVID patients can show increased levels of inflammatory cytokines (immune signalling proteins), which may contribute to persistent symptoms.
LDN has demonstrated effects on immune and inflammatory signalling in other conditions, which is one reason it is being explored for Long COVID.
LDN may help some people by “turning down” overactive immune signalling and neuro-inflammation, which could reduce symptoms like fatigue, pain, and brain fog — but this remains an active area of research.
📚 What studies have been published?
The evidence base is still early. The strongest signals so far come from small studies and observational reports.
Study: Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
Journal: Brain, Behavior, and Immunity – Health (2022)
This interventional pre–post study reported improvements in some self-reported symptoms (including pain and energy) and found LDN was generally tolerated.
Limitations include the absence of a placebo group and a relatively small sample size.
Study: Pilot study of LDN combined with NAD+ for persistent fatigue after COVID-19
Journal: Frontiers in Medicine (2024)
Participants reported improvements in fatigue and quality of life. However, this was combination therapy (LDN + NAD+), so it does not prove LDN alone caused the benefit.
Study: Low dose naltrexone restores TRPM3 ion channel function in natural killer cells from patients with Long COVID
Journal: Frontiers in Immunology (2024)
This study supports a biological rationale for LDN, but it is lab-based and does not prove symptom improvement in everyday life.
⚠️ Important balance: LDN is not a cure
It’s important to encourage hope while avoiding the belief that one medicine will cure Long COVID.
LDN may be helpful for some people, but it is usually best seen as one part of a broader treatment plan.
🧪 Are better trials underway?
Yes. Placebo-controlled trials are underway or planned in several regions, including fatigue-focused studies.
These trials aim to clarify:
- Does LDN work better than placebo?
- Which symptom patterns respond best?
- What is the best dose and duration?
LDN remains a promising but still emerging option while larger, higher-quality trials are completed.
👥 Who might be a sensible candidate to consider LDN?
Based on current clinical use and early studies, LDN is most often considered for Long COVID patients whose main symptoms include:
- persistent fatigue
- widespread pain or fibromyalgia-like features
- sleep disturbance
- cognitive symptoms (“brain fog”)
Long COVID appears to involve multiple biological pathways. A treatment that helps one symptom pattern may not help another — which is why careful assessment and patient selection are essential.
🛡️ Safety, side effects, and cautions
LDN is often described as well tolerated, but some people report side effects — particularly early on — such as sleep disturbance or feeling “not quite themselves”.
Possible side effects include:
- vivid dreams or insomnia
- headache
- nausea / gastrointestinal upset
- agitation or “wired” feeling early on
LDN blocks opioid receptors. It should generally not be used alongside opioid pain medication.
If opioids are involved, specialist guidance is essential.
🌟 How Pain Spa may be able to help
At Pain Spa, we take an evidence-informed and individualised approach to Long COVID, recognising that symptoms can have multiple drivers — including immune dysregulation, neuro-inflammation, nervous system sensitisation, and autonomic dysfunction.
Where appropriate, and following careful discussion of the evidence and limitations, low-dose naltrexone (LDN) may be considered as part of a broader symptom-management plan.
We focus on safety, realistic expectations, and monitoring response over time, rather than positioning any single medication as a “cure”.
LDN is a promising off-label option with early supportive studies, but larger placebo-controlled trials are still needed.
For selected patients, it may be a helpful part of an individualised Long COVID management plan.